Clinical trial · Interventional
Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma
Phase II Study of Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Malignant Mesothelioma
NCT00137826CI-TRIAL-00005980completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether the combination of the investigational drugs Avastin and Tarceva are effective in patients with mesothelioma who have previously been treated with chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Mesothelioma | Malignant Mesothelioma | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bevacizumab | Drug | Bevacizumab | ALIAS |
| Erlotinib | Drug | Erlotinib | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To determine the response to the combination of bevacizumab and erlotinib in previously treated malignant mesothelioma
- timeFrame
- 3 years
Secondary outcomes (4)
- measure
- To determine the time to tumor progression
- measure
- to determine the duration of response
- measure
- to determine the median and overall survival of patients
- measure
- to determine the safety of the drugs administered
- timeFrame
- 3 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Mesothelioma that has been previously treated with at least one chemotherapy regimen * 18 years of age or older * Must at least be able to walk and capable of taking care of oneself although unable to carry out work activities * Four or more weeks since last major surgery * Four or more weeks since last radiation therapy * Three or more weeks since last chemotherapy * Life expectancy of 12 weeks or more * Blood tests that show kidneys, liver and bone marrow to be working adequately * Able to comply with study and/or follow-up procedures Exclusion Criteria: * Prior exposure to Tarceva (OSI-774, erlotinib), trastuzumab, ZD1839 or C225 * Receiving anticoagulation medication other than low dose Coumadin * Clinically significant heart disease such as uncontrolled hypertension, previous heart attack within past 12 months, uneven heartbeat, etc. * History of central nervous system disease such as seizures not controlled with standard medical therapy, brain metastases or history of stroke * Major surgery within 28 days of screening * Daily treatment with aspirin or anti-inflammatory medications * Pregnant or lactating (pertaining to women only) * Serious or nonhealing wound, ulcer or bone fracture * Difficulty swallowing * A disease or disorder that interferes with ability to digest and absorb food * History of coughing up more than 1/4 teaspoon of blood * A medical condition that could make it unsafe for patient to participate in this study
References
Publications (2)
- BACKGROUNDShepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005 Jul 14;353(2):123-32. doi: 10.1056/NEJMoa050753. PMID 16014882
- BACKGROUNDPerez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabarbara P, Bonomi P. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol. 2004 Aug 15;22(16):3238-47. doi: 10.1200/JCO.2004.11.057. PMID 15310767